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Introduction
There  have  been  important  recent  advances  in
understanding the molecular mechanisms of atopy in
terms  of  identification  of  key  cells,  the  role  of
cytokines and other mediators, and the cell signalling
pathways involved. This has given new insights into
the epidemiological trends in atopic diseases and has
provided novel molecular targets for the development
of new therapies.1,2
Immunoglobulin E
Production of specific  immunoglobulin  (Ig)E  is the
characteristic abnormality of atopy. IgE is produced by
B lymphocytes under the influence of interleukin (IL)-
4 and IL-13. IgE binds to high-affinity IgE receptors
(Fc«RI)  on  mast  cells  to  induce  degranulation  and
mediator synthesis.  IL-4  enhances the  activation of
Fc«RI  to augment  the production of  cytokines and
lipid  mediators.3 These  receptors  may  also  be
expressed on other cells such as basophils, monocytes
and eosinophils. IgE may also activate low-affinity IgE
receptors (Fc«RII or CD23) that are expressed on B
lymphocytes, T lymphocytes, macrophages and airway
smooth muscle cells.4 CD23 expression is enhanced by
IL-4. Recently, a humanised murine monoclonal anti-
body (E25) directed against IgE has demonstrated a
reduction  in  early  and  late  responses  to  inhaled
allergen and eosinophil counts in induced sputum, and
reduced  airway  hyperresponsiveness.5,6 There  is  a
profound reduction in circulating IgE, which may be
due to switching-off IgE production from B cells. In
patients with severe asthma who require oral steroids
there is a significant reduction in oral steroid require-
ments,  and  several  patients  are  able  to  completely
withdraw oral steroids in comparison with a placebo.7
E25 may also reduce signalling through CD23 as IgE
levels are lowered and this might explain its efficacy in
chronic  asthma,  through  an  inhibitory  effect  on T
lymphocytes,  macrophages,  eosinophils  and  airway
smooth muscle.8
T lymphocytes
T lymphocytes play a pivotal role in orchestrating the
inflammatory response in atopic diseases, through the
release of specific cytokines, resulting in the recruit-
ment  and  survival  of  eosinophils  and  in  the  main-
tenance of mast cells in the airways.  T lymphocytes are
coded to express a distinctive pattern of cytokines,
which may be similar to that described in the murine T
helper  cell  (Th)2  type  of  T  lymphocytes,  which
characteristically express  IL-4,  IL-5  and  IL-9 and  IL-
13.9,10 This  programming  of T  lymphocytes  is  pre-
sumably due to antigen-presenting cells, particularly
dendritic cells. There appears to be an imbalance of Th
cells  in  atopic  diseases,  such  as  asthma,  with  the
balance tipped away from the normally predominant
Th1 cells in favour of Th2 cells. The balance between
Th1 cells and Th2 cells may be determined by locally
released cytokines, such as IL-12 and IL-4.
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promote Th1-mediated responses to predominate and
that a lack of infection and exposure to endotoxins in
childhood may favour Th2 cell expression, and thus
atopic diseases.11Th2 cells predominate in the foetus
but, during neonatal life, there is an increase in Th1
cells that may be driven by exposure to bacterial and
viral infections and endotoxins. Reduced exposure to
these environmental factors may thus lead to perpetu-
ation of Th2 cells and the development of atopy; the
so-called ‘hygiene hypothesis’ of atopy.12
Antigen-presenting cells
Dendritic cells
Dendritic cells are specialised macrophage-like cells
in  the  airway  epithelium  that  are  very  effective
antigen-presenting cells,13 and therefore play a very
important  role  in  the  initiation  of  allergen-induced
responses  in  asthma  and  other  atopic  diseases.
Dendritic  cells  take  up  allergens,  process  then  to
peptides  and  migrate  to  local  lymph  nodes  where
they present the allergenic peptides to uncommitted
T  lymphocytes,  to  programme  the  production  of
allergen-specific T cells. Immature dendritic cells in
the respiratory tract promote Th2 cell differentiation
and  require  cytokines  such  as  IL-12  and  tumour
necrosis  factor-a (TNF-a)  to  promote  the  normally
preponderant Th1 response.14
Macrophages
Airway macrophages may also act as antigen-present-
ing cells that process allergen for presentation to T
lymphocytes, although alveolar macrophages are far
less effective in this respect than macrophages from
other  sites,  such  as  the  peritoneum.  Macrophages
normally  have a ‘suppressive’ effect on lymphocyte
function,  but  this may  be  impaired in  asthma after
allergen exposure.15 Macrophages may therefore play
an important anti-inflammatory role, preventing the
development of allergic inflammation.
Antigen presentation
The molecular mechanisms involved in antigen pre-
sentation are now well described. Antigenic peptides
processed  by  the  antigen-presenting  cell  are  pre-
sented on class II major histocompatibility complex
molecules to receptors on helper (CD4+) T lympho-
cytes. Co-stimulatory molecules play a critical role in
augmenting the interaction between antigen present-
ing  cells  and  CD4+ T  lymphocytes. The  interaction
between B7 and CD28 may determine whether a Th2-
type  cell  response  develops,  and  there  is  some
evidence  that  B7–2  (CD86)  skews  towards  a Th2
response.  Blocking  antibodies  to  B7–2  inhibit  the
development of specific IgE, pulmonary eosinophilia
and AHR in mice, whereas antibodies to B7–1 (CD80)
are ineffective.16 A molecule on activated T-cell CTL4
appears to act  as  an endogenous inhibitor of T-cell
activation,  and  a  soluble  fusion  protein  construct
CTLA4-Ig is also effective in blocking airway hyper-
responsiveness (AHR) in a murine model of asthma.17
Anti-CD28,  anti-B7–2  and  CTLA4-Ig  all  block  the
proliferative response of T cells to allergen,18 indicat-
ing that these are potential targets for novel therapies
that might be effective in atopic diseases.
Structural cells
Structural  cells  of  the  airways,  including  epithelial
cells,  fibroblasts  and  even  airway  smooth  muscle
cells, may also be an important source of inflamma-
tory mediators, such as cytokines and lipid mediators
in  asthma.19,20 Indeed,  because  structural  cells  far
outnumber inflammatory cells, they may become the
major source of mediators driving chronic inflamma-
tion in asthmatic airways. In addition, epithelial cells
may play a key role in translating inhaled environmen-
tal signals into an airway inflammatory response and
are  probably  a  major  target  cell  for  inhaled
corticosteroids.
Role of cytokines
Cytokines are important in the chronic inflammation
of asthma and play a critical role in orchestrating the
allergic  inflammatory  response.21,22 The  cytokines
that appear to be of particular importance in asthma
include the lymphokines secreted by Th2 cells.
Interleukin-4
IL-4 is critical in switching B lymphocytes to produce
IgE,  for  expression of VCAM-1 on endothelial cells,
and for inducing the differentiation of Th2 cells and IL-
5, which is essential for the differentiation of eosino-
phils.  IL-4  is  of  critical  importance  in  the  differ-
entiation of Th2 cells and is therefore an ‘upstream’
cytokine that is an attractive therapeutic target in the
treatment of atopic diseases. This is reinforced by the
demonstration that a soluble receptor for IL-4 (altra-
kincept),  given  by  inhalation,  has  a  steroid-sparing
effect in patients with moderately severe asthma.23 IL-
4  also  enhances  IgE-mediated  activation  of  mast
cells.3
Interleukin-13
There is increasing evidence that IL-13 in mice mimics
many  of  the  features  of  asthma,  including  AHR,
increased IgE, mucus hypersecretion,24 and induces
the secretion of eotaxin form airway epithelial cells.25
IL-13 signals through the IL-4 receptor a-chain, but
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it may be an important target for the development of
new therapies. A soluble IL-13Ra2-Fc fusion protein,
which blocks the  effects of  IL-13  but  not IL-4,  has
been used successfully to neutralise IL-13 in mice in
vivo.24
The IL-13Ra2-Fc  fusion  protein markedly inhibits
the eosinophilic inflammation, AHR and mucus secre-
tion induced by allergen exposure. IL-13 is expressed
in  asthma  to  a  much  greater  extent  than  IL-4,
indicating that it may be a more important target.27
This  suggests  that  development  of  IL-13  blockers,
such as a humanised IL-13 antibody or the IL-13Ra2,
may  be  a  useful  approach  to  the  treatment  of
established allergic diseases.28
Interleukin-5
The  critical  role  of  IL-5  in  eosinophilia  has  been
confirmed  by  the  use  of  an  anti-IL-5  antibody  in
asthmatic patients, which almost depletes circulating
eosinophils and prevents eosinophil recruitment into
the airway after allergen.29
Interleukin-9
Another Th2 cytokine, IL-9 may play a critical role is
sensitising responses the cytokines IL-4 and IL-5.30
Interleukin-12
IL-12 is the endogenous regulator of Th1 cell develop-
ment and determines the balance between Th1 and
Th2  cells.31 IL-12  administration  to  rats  inhibits
allergen-induced inflammation32 and inhibits sensiti-
sation to allergens. IL-12 releases interferon-g (IFN-g),
but has additional effects on T-cell differentiation. In
mice, administration of an IL-12-allergen fusion pro-
tein  results  in  the  development  of  a  specific Th1
response  to  allergens  rather  than  the  normal Th2
response  with  IgE  formation.33 This  indicates  the
possibility of using IL-12 to provide a more specific
immunotherapy,  which  might  even  be  curative  if
applied early in the course of the atopic disease. We
have  demonstrated  that  IL-12  therapy  in  asthmatic
patients reduces circulating eosinophils and eosino-
phils in induced sputum, but does not affect under-
lying AHR or response to allergen, and is associated
with significant toxicity.34
Interleukin-18
IL-18, also known as IFN-g-inducing factor, is an IL-
1-like  molecule  that  acts  like  IL-12  to  induce  the
release of IFN-g from Th1 cells, and thereby suppress
Th2  cells.35 Unlike  IL-12m  however,  it  does  not
promote the differentiation of Th1 cells.
Interferon-g
IFN-g inhibits Th2  cells  and  mediates many  of  the
inhibitory  effects  of  IL-12.  In  sensitised  animals,
nebulised  IFN-g inhibits  eosinophilic  inflammation
induced  by  allergen  exposure.36 Administration  of
IFN-g by nebulisation  to asthmatic patients did not
significantly reduce eosinophilic inflammation, how-
ever (possibly due to the difficulty in obtaining a high
enough concentration locally in the airways).37 Aller-
gen  immunotherapy  increases IFN-g production by
circulating T cells in patients with clinical benefit38
and  increases numbers  of  IFN-g-expressing  cells  in
nasal biopsies of patients with allergic rhinitis.39
Interleukin-10
IL-10  is  a  potent  anti-inflammatory  cytokine  that
inhibits the synthesis of many inflammatory proteins,
including cytokines (TNF-a, granulocyte macrophage-
colony  stimulating  factor,  IL-5,  chemokines)  and
inflammatory  enzymes  (inducible  nitric  oxide  syn-
thase) that are over-expressed in  asthma.40 In  addi-
tion, IL-10 inhibits antigen presentation and sensitisa-
tion.  Indeed,  there  may  be  a  defect  in  IL-10
transcription  and  secretion  from  macrophages  in
asthma.41,42. In sensitised animals, IL-10 is effective in
suppressing the inflammatory response to allergen,43
suggesting  that  IL-10  might  be  defective  in  atopic
diseases. IL-10 may play a key role in the mechanism
of allergen immunotherapy.44 Polymorphisms of the
IL-10 promoter may be a determinant of severity in
allergic disease such as asthma.45
Therapeutic implications
There  is  persuasive  evidence  that  lack  of  early
infections and a clean environment may increase the
risk of atopy in a genetically predisposed individual.
This  has  suggested  novel  therapeutic  strategies  to
prevent atopic diseases, including exposure to bacte-
rial product to stimulate a Th1-type immunity and to
increase IL-12 secretion.1,11
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Introduction
Although  there are  many  possible  explanations  for
the  increase  in  asthma,  they  can  be  simplified  to
three. The first  was proposed as early  as 1980  and
was based on epidemiology from  a  small  group  of
countries in each of which the increase was related
to  dust  mite  sensitivity.1–3 This  hypothesis  focused
on  the  increase  in  exposure  that  had  occurred
secondary to changes in housing and lifestyle. Over
the next 10 years, it became obvious that increases
had occurred in many countries and regions where
dust mites were not the  dominant indoor allergen.
In  Sweden  and  Finland,  the  increase  was  clearly